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Introduction: Radio-frequency ablation (RFA) is a promising minimal-invasive treatment option for early liver
cancer, however monitoring or predicting the size of the resulting tissue necrosis during the RFA-procedure is a
challenging task, potentially resulting in a signiﬁcant rate of under- or over treatments. Currently there is no
reliable lesion size prediction method commercially available.
Objectives: ClinicIMPPACT is designed as multicenter-, prospective-, non-randomized clinical trial to evaluate
the accuracy and eﬃciency of innovative planning and simulation software. 60 patients with early liver cancer
will be included at four European clinical institutions and treated with the same RFA system. The pre-
interventional imaging datasets will be used for computational planning of the RFA treatment. All ablations will
be simulated simultaneously to the actual RFA procedure, using the software environment developed in this
project. The primary outcome measure is the comparison of the simulated ablation zones with the true lesions
shown in follow-up imaging after one month, to assess accuracy of the lesion prediction.
Discussion: This unique multicenter clinical trial aims at the clinical integration of a dedicated software solution
to accurately predict lesion size and shape after radiofrequency ablation of liver tumors. Accelerated and op-
timized workﬂow integration, and real-time intraoperative image processing, as well as inclusion of patient
speciﬁc information, e.g. organ perfusion and registration of the real RFA needle position might make the in-
troduced software a powerful tool for interventional radiologists to optimize patient outcomes.
1. Introduction
Liver cancer has several treatment options, while each approach
comes along with speciﬁc limitations. For hepatocellular cancer (HCC)
chemotherapy often has unsatisfactory results [1], whereas surgery
(resection or transplant) can be curative, but is not always suitable
especially for older patients with existing comorbid conditions, e.g.
liver cirrhosis [2]. Therefore adequate patient selection is of paramount
importance [3,4]. Radiofrequency ablation (RFA) has become the ﬁrst
treatment choice for early-stage HCC in cirrhotic livers [5]. Also, for
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early metastatic liver cancer in inoperable patients, RFA is considered a
viable alternative with comparable overall survival [6]. Percutaneous
RFA oﬀers minimal invasiveness due to precise image guidance and
reliable needle placement. Ultrasound (US) or computed tomography
(CT) guided RFA is the most commonly used ablation technique
worldwide.
Although RFA requires a relatively low technical eﬀort compared to,
e.g., cryo- or lasertherapy, one cannot currently monitor therapy in real
time, which can cause signiﬁcant discrepancies between the expected
and real sizes of ablation zones. This potentially results in an over- (up
to 9% of major complications) [7], or under treatment (up to 40% local
recurrence) [7,8].
The ClinicIMPPACT proposal is based on the results of the IMPPACT
project, in which we created a model for facilitating accurate RFA
treatments [9,10]. The required software was developed during
IMPPACT and basically provides a simulator for radiologists to plan,
review and optimize procedures. With IMPPACT, extensive experiments
were performed on cells and animals to create a heat dependent cellular
death model, which was implemented into the simulation algorithm.
The histological workups of the RFA-induced lesions in porcine liver
were used to calibrate the preliminary RFA model. Subsequently, eight
lesions were selected from a database of accurately documented clinical
procedures, and the software was used to retrospectively simulate in-
terventions and predict lesion shapes (Fig. 1).
The predicted volumes were then compared to the real thermal le-
sions visualized and segmented in contrast-enhanced CT one month
after ablation. These comparisons showed that simulated and real le-
sion volumes matched acceptably, after taking virtual tissue perfusion
values into account. Individual perfusion parameters are essential for
an accurate lesion prediction because intrahepatic tumor/vessel
proximity can cause unwanted heat transfer during radiofrequency
ablations. Some lesion shapes were mismatched, possibly due to in-
accuracies in segmenting non standardized radiological images [11].
Our hope is, that the treatment of early liver cancer with RFA could
be improved using a validated software solution to estimate lesion size
and identify possible complications in advance. Self-evident, such a
solution has to be adapted to real-time clinical requirements.
The ﬁrst goal of ClinicIMPPACT is to reﬁne an existing simulation
tool, driven by a user-friendly, ergonomically optimized graphical user
interface, to support the complex requirements of clinicians performing
radiofrequency ablations of liver tumors. Therefore, the working steps
of this European joint research project and its partners are to accelerate
simulation speed, optimize the graphical user interface, enable patient
speciﬁc needle registration, and integrate patients' individual perfusion
values into the software calculations. The second aim of this trial is to
ensure an accurate validation and to produce reliable predictions
during the interventional procedure.
2. The ClinicIMPPACT study protocol
2.1. Study management
The ClinicIMPPACT project is a multicenter, non-randomized pro-
spective clinical trial funded by the Seventh Framework Program of the
European Union (grant number 610886). The original proposal was
designed and conducted by the Fraunhofer Institute for Applied
Informational Technologies (FIT) in St. Augustin (Germany) in colla-
boration with medical and technical partners, which are listed below.
The medical aspect of the study is shared between four university
hospitals located in Turku (Finland), Graz (Austria), Nijmegen
(Netherlands), and Leipzig (Germany). The local study center of the
University of Leipzig (ZKS, Center for Clinical Studies) is responsible for
monitoring patient safety and adherence to good clinical practice. Each
medical unit consists of a project leader (experienced interventional
radiologist) and one or two assistants (e.g. resident radiologists).
Technical partners, who provide the software development and data
implementation, are located at Graz (Austria), Helsinki (Finland), and
Dundalk (Ireland). Approvals were granted by the institutional ethics
committees and the German Federal Oﬃce for Radiation Protection
(Bundesamt für Strahlenschutz, BfS, only necessary for Leipzig,
Germany). The study has been registered at clinical trial databases
(http://drks-neu.uniklinik-freiburg.de/drks_web/, and https://
clinicaltrials.gov).
2.2. Study population eligibility
All participating subjects are patients (both men and women) with
primary (hepatocellular carcinoma, HCC) or secondary (e.g. colorectal
metastasis) malignant liver tumors who are referred for RFA treatment
after interdisciplinary consent of the local tumor board (consisting of
radiologists, oncologists and hepatobiliary surgeons), according to
AASDL guidelines for HCC (http://www.aasdl.org) and inter-
disciplinary agreement for secondary liver tumors regarding oper-
ability, patient safety and compliance. All patients must also fulﬁll the
standard eligibility criteria for undergoing preinterventional diagnostic
such as contrast enhanced multiphase CT of the abdomen and perfusion
CT of the liver. Table 1 shows the complete list of criteria.
2.3. Trial design and enrollment
The trial ﬂow chart and the visit schedule are given in Fig. 2 and
Table 2, respectively. Each trial participant (15 per clinical site, 60
patients in total) requires a pre-existing primary or secondary tumor of
the liver, preferably shown in two independent imaging modalities,
Fig. 1. Actual segmented versus simulated lesion shape. IMPPACT Project, Grant
Number: 223 877; FP7.
Table 1
Overall inclusion and exclusion criteria for the ClinicIMPPACT Trial (for both imaging
and RFA).
Inclusion criteria
• Age > 18 years.• Diagnosis according to AASDL guidelines for HCC.• Surgical resection or other preferable treatment options were not given.• Maximum of 3 lesions with a maximum diameter of 3 cm.• Suﬃcient coagulation parameters according to ESIR guidelines (http://www.esir.
org).
• Informed consent after thorough information through the patients' radiologist.
Exclusion criteria
• Rejection by the patient (although patient may stop treatment/intervention at
any time).
• Known anaphylactic reaction to iodine/contrast agent for acquisition of
diagnostic/perfusion CT.
• Malfunction of the kidney or the thyroid gland.• Splenectomy.• Pregnant or nursing women.• Concurrent participation in other interventional trials.
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alternatively histologically proven. Decisions on optimal therapies will
be conducted through each local tumor board, which will evaluate
options such as surgical resection, liver transplantation, adjuvant or
neoadjuvant chemotherapy or image guided procedures such as RFA.
2.4. Pre-interventional diagnostic imaging
Preinterventional diagnostic imaging is substantial for a successful
therapy of liver tumors [12,13]. In this study, diagnostic imaging
contains contrast enhanced multiphase abdominal CT and an additional
perfusion scan of the liver. Even though MR imaging [14] is a promising
and well established examination tool for liver disease, CT images are
necessary for quantitative CT perfusion measurement, planning and
segmentation prior to RFA and for image guidance as part of the
intervention in this study.
Multiphase diagnostic CT imaging will be performed as part of the
clinical routine comprising the parameters shown in Table 3. Patients
should fast at least 4 h prior to the examination. Oral contrast agent will
not be used. Rather, intravenous contrast agent will be injected at a
ﬂow rate of 3 ml/s (contrast agent ≥300mlg/ml) and CT scans will be
conducted in the arterial, portal venous and venous contrasting phase.
Total contrast volume will depend on body weight. All images will be
acquired during breathold in expiration, with elevated arms, if possible.
2.4.1. Perfusion CT of the liver
It is known that perfusion is eﬀectively a source of tissue cooling
and may substantially aﬀect heat transfer and ultimately the size of the
induced thermal lesion [15]. The double blood supply of the liver can
Fig. 2. Flow chart of the ClinicIMPPACT Trial.
Table 2
Visit schedule for ClinicIMPPACT Trial subjects.
Follow-up
Treatment/Procedure Visit 1(baseline) Visit 2(RFA) Visit 3(1 mo)a Visit 4(3 mo)a Visit 5(6 mo)a Visit 6(12 mo)a
Informed consent ●
Inclusion criteria ●
Exclusion criteria ●
Demographic data ●
Physical examinationb ● ●
Anamnesis ● ●
Concomitant diseases ● ●
CT (Soc) ● ● ● ● ●
Perfusion CT (Nsoc) ●
Complications ● ● ● ● ●
Concomitant medication ● ●
Occurrence of tumor ● (Soc) ● (Soc) ● (Soc) ● (Soc)
Nsoc = Not standard of care Soc = Standard of care.
a Months after RFA.
b Physical examination includes height, weight, blood parameters, Karnofsky – score, ECOG - status.
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diﬀer signiﬁcantly between individuals, e.g. patients with liver cirrhosis
show a higher ﬂow in the hepatic artery while the portal venous ﬂow is
strongly reduced which leads to a lower overall perfusion [16,17],
compared to healthy liver tissue. Dynamic CT measurements after
contrast administration (Perfusion CT, PCT) can be used to quantify
tissue perfusion in the liver [17].
The IMPPACT project (Grant No. 223877, completed in February
2012) has shown that the inclusion of patient-speciﬁc perfusion values
in the heat transfer calculation can substantially improve the accuracy
of the simulated lesion size [18].
A dedicated imaging protocol (Table 4) had to be developed to meet
a low radiation exposure with adequate image quality. Some of the key
examination factors were:
(a) The use of a peripheral venous catheter (preferably 18G) to enable a
high injection rate (at least 6 ml/s);
(b) A quick contrast injection (8–10 s bolus)
(c) A small volume of contrast agent 40 ml followed by a 30-ml saline
chaser;
(d) Data acquisition under shallow breathing to improve patient com-
fort and reduce liver motion.
2.4.2. CT perfusion analysis
Over the past years, a number of diﬀerent techniques, both in re-
search as well as commercial tools, have been used to quantify liver
perfusion with CT [17,19]. Quantitative parameters such as arterial
liver perfusion (ALP), portal venous perfusion (PVP), blood ﬂow (BF),
blood volume (BV), or capillary permeability can be derived from the
time course of the contrast related signal increase depending on the
speciﬁc mathematical method used, e.g. deconvolution [17] or max-
imum slope [20]. Results from diﬀerent methods however, are not
necessarily interchangeable as has recently been suggested in a study
that analysed the same raw data [19].
The four clinical partners of the ClinicIMPPACT project use CT
scanners from three diﬀerent manufactures (Siemens, Philips and
Toshiba). Development of a common software tool for standardized CT
data analysis was therefore essential [18]. Arterial and portal venous
perfusion, both measured in ml/min/100 ml, were identiﬁed as the
most important perfusion parameters related to the microcirculation in
non-tumorous parenchyma. The maximum slope (MS) method was
chosen because of several speciﬁc advantages, in particular its
robustness, independence from model assumptions and eﬃcient use of
data over the ﬁrst 40 s only.
The performance of the PCT tool was tested on seven perfusion data
sets by comparing its results with those from a commercial maximum-
slope analysis tool (VPCT, Siemens Healthcare, Erlangen, Germany).
Regions of interest (ROI) were visually placed at the same positions
with both tools. The comparison showed good absolute agreement of
total liver perfusion between both software tools (Fig. 3). The PCT tool
was therefore used for all further analyses within this study [18].
2.5. Radiofrequency ablation
2.5.1. Real-time RFA prediction
Requires fast extraction and alignment of the heat sources during its
execution. Since the 3D model of the liver is built oﬄine from the
preoperative CT data, the heat source (i.e., the needle) must be regis-
tered with this precomputed model during the RFA procedure.
For this project, we will rely on image based registration. Some
algorithms are available to register interventional and preoperative
liver data, using either rigid [22] or non-rigid transformations [23,24].
The accuracy of rigid needle registration [25] tends to be higher than
the accuracy limit of 5.0 mm agreed up on by the project medical
partners. Thus, the project designed a novel registration method that
oﬀers both fast computing (< 2 min) and accuracy (average absolute
error < 5.0 mm).
Real-time simulation of RFA cancer treatment requires fast solvers
to predict heat transfer and cell death evolution, which can be non-
linear due to temperature dependencies, and therefore computationally
expensive. In the IMPPACT project a prototype for RFA simulation [26]
was developed, that fulﬁlls the basic requirements of computer assisted
intervention planning (screenshot: Fig. 4), and provides state of the art
visualization for RFA. Other tools and prototypes use either simpliﬁed
abstractions of the heating areas [27,28] or heat distribution simula-
tions which do not perform in accordance with our requirements re-
garding precision [29,30]. The earlier IMPPACT tool derived from the
Table 3
Scan parameters for diagnostic CT imaging.
Parameters Native scan Arterial phase Portal venous phase Venous phase
Coverage Area Liver Liver Liver to Symphysis Liver
Delay (s) – 15 45 60
Collimation (mm) (256) × 0.625 (256) × 0.625 (256) × 0.625 (256) × 0.625
Rotation time (s) 0.75 0.75 0.75 0.75
mAs 180 220 250 250
kV 120 120 120 120
Reconstruction (mm) 2 2 2 2
Increment (mm) 0.5 0.5 0.5 0.5
Table 4
Parameters for perfusion CT imaging.
Parameters Native Contrast-enhanced phase
Coverage area Liver Liver
Number of cycles – 30
Interval between cycles (sec) – 1.5
Collimation (mm) (256) × 0.625 –
kVp 80 80
mAs 120 100
Pitch 0.933 0
Slice thickness (2 mm) 2 2.5
Fig. 3. Comparison of total perfusion (ALP + PVP, in ml/min/100 ml) in normal liver
parenchyma (average of three ROIs) in seven patients between custom made (PCTool)
and commercial analysis software (VPCT, Siemens Healthcare).
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initial project was the ﬁrst to consider cell death instead of simple heat
approximations for its simulation. However, this tool was unable to
perform real-time simulations, actual planning of a treatment could
take several hours. Needle positions, which may vary during the real
intervention from the planned procedure and changes in the patients'
anatomical conditions, cannot be treated correctly with the currently
available tools.
The complete reﬁnement of the presented RFA simulation tool has
been currently ﬁnalized. Diﬀerent data representations have to be
combined and processed upon the start of the clinical study. Processing
such diﬀerent data modalities in a single algorithm is called “multi-
variate data processing.” ClinicIMPPACT will therefore improve the
ﬁeld of multivariate data processing with real-time measures to visua-
lize combined (structured) clinical CT data, (unstructured) simulation
data and surface based segmentation data in a single ﬁrst step. This can
be achieved by dedicated methods, using a modern graphics processing
unit (GPU) [9,31,32].
The aim is to study the optimal balance between uncertainty
awareness and multivariate data representation in an initial study, and
reﬁne our methods during the clinical phase of this project. Thereby the
current state of medical uncertainty visualization will be enhanced and
the conveyance of additional information for already complex base
visualizations will be improved.
2.5.2. Clinical RFA intervention
The clinical protocol for RFA includes a sequence of steps and
procedures, i.e. patient data acquisition, data analysis, intervention
procedures, etc. (Table 5), carried out by an experiences IR at all four
clinical sites. The RFA software tools are designed to support IRs at each
step of the RFA, and will be installed locally on a server in the inter-
vention room. As the software is optimized to suit the standard clinical
RFA procedure, no changes are necessary to the clinical workﬂow.
Every procedure will be documented by a speciﬁc checklist/case report
form that covers the patients' details, size and number of lesions, etc.
First, a non-enhanced CT scan with the patient under full anesthesia
will be performed to localize tumors and plan the optimal needle access.
As the IR inserts the needle under CT guidance, in-room visualization of
the 3D model begins. Once the IR is satisﬁed with the needle position, the
hooks are completely deployed and a non-enhanced CT scan (breathing
being temporarily held in expiration) is performed. The IR will conﬁrm
that the deployed needle is in the proper treatment position on CT scans;
CT data is then transferred to the external PC for fast needle registration,
which semi-automatically registers the needle into the 3D model [10].
The next step is the simultaneous start of the RFA and the computer
simulation of the lesion, following a standard or a modiﬁed ablation
protocol (Table 6). Optionally, after the intervention, a control CT with
contrast agent is performed in breath-hold technique. In case the lesion
is not suﬃciently treated, needle adjustment and additional ablation
will be performed under CT-guidance. If the ablation result is suﬃcient,
the needle is removed by ablating its track and the treatment is ﬁnished.
2.6. Follow up imaging
Follow up imaging will be performed 1, 3, 6, and 12 months after
RFA via multiphase CT (non-enhanced, arterial, portal venous, venous)
for HCC lesions or by monophasic CT (portal venous) for, e.g., (color-
ectal) metastases in expiration. All CT images, whether pre-, peri- or
postinterventional (i.e. follow up) will be evaluated by radiologists with
more than 10 years of experience in abdominal imaging, at each par-
ticipating medical site.
2.7. Stopping rules
Patients may withdraw their consent to participate at any time
without giving reasons. However, these patients should be asked for
their reasons for premature termination after being informed that he/
she does not need to do so. Information as to when and why a patient
was registered and when he/she withdrew consent must be retained in
the documentation. Patients are to be informed that if they revoke
Fig. 4. Prototype for a clinical interface that was developed
during the initial IMPPACT project. The needle position and
RFA protocol can be selected to provide a patient-speciﬁc
simulation of the predicted cell death. This simulation
usually took several hours, which made its clinical use im-
practical.
Table 5
Clinical RFA algorithm.
Step Clinical protocol
1 Interventional native planning CT for tumor localization and access
planning
2 CT-guided needle insertion
3 Control CT scan in end-expiratory apnea to visualize deployed needle
4 Registration of the real needle position into the 3D model
5 Computer simulation of the RFA lesion
6 Selection of the appropriate therapy protocol by the IR and start of RFA
independent of the simulation results
7 Immediate acquisition of control CT with CE in end-expiratory apnea
I. Lesion not adequately ablated (repeat from step 4 in case of needle
replacement)
II. Adequate ablation (move on to step 8)
8 Removal of probe (while ablating track); termination of anesthesia
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consent the stored data may be used further, as the data may be ne-
cessary to (a) assess eﬀects of the software being tested; (b) guarantee
that the patients' personal interests are not adversely aﬀected; and (c)
comply with the requirement to provide complete authorization doc-
umentation.
Furthermore, the trial can be terminated prematurely by the co-
ordinating investigator in the event of (a) serious adverse events; (b)
changes in the risk/beneﬁt considerations, e.g., as a result of un-
expected adverse events; (c) new insights from other trials; or (d) an
insuﬃcient recruitment rate. The ﬁnal decision regarding the pre-
mature termination of the trial will be made by the coordinating in-
vestigator or his/her authorized representative.
Data captured in the clinical trial, which cannot be used for trial
analyses due to a patients' premature trial termination may be used for
clinical decisions (such as staging), if this is beneﬁcial to the patients'
treatment. Premature trial terminations must be documented, as pre-
cisely as possible, with the date and (if possible) reasons and circum-
stances and submitted to the data management and the coordinating
investigator as soon as possible.
As follow up care is based on the guidelines for liver carcinoma
treatment and is not part of this trial, premature terminations of follow
ups can be neglected. A potential reason for premature termination of
follow up might the need for a patient to travel long distances to the
trial site. In such cases, we will attempt to obtain the CT data from the
patients' treating radiology department (pending the patients' consent).
2.8. Objectives
The primary objective of this study is the comparison of the size and
shape of the real ablation zone one month after a RFA treatment of liver
tumors with the simulation results of the ClinicIMPPACT software. This
information will help evaluate the accuracy of the prediction.
The secondary objectives of this study are the evaluation of the
workﬂow steps and the clinical feasibility of the ClinicIMPPACT pro-
cedure. We will also analyze if there is a potential beneﬁt for the pa-
tient, i.e. if the simulation result would have been known by the
treating IR, would it have inﬂuenced the treatment protocol? By design
the IRs were not allowed to take the simulation results into con-
sideration during the intervention.
2.9. Statistical analysis
This trial aims at the collection of pilot clinical data, not to verify a
speciﬁc hypothesis. Hence it is not possible to determine a sample size
in the traditional sense by specifying a concrete alternative hypothesis
and requiring a certain power. For the primary endpoint, we will
compare lesions, on a level of volume- and surface deviation, visualized
by routine CT one month after an ablation with their simulated coun-
terparts to deﬁne the accuracy of the method itself. The coinciding
volumes of the real RFA lesion and the simulated one will be de-
termined by counting the number of matching voxels, i.e. voxels of
simulation and recorded data, sharing the space coordinates, and di-
viding by the sum of the voxels of simulated and real lesions.
Normally distributed data will be described with means and stan-
dard deviations and skewed variables will be described with medians
and interquartile ranges. Paired t-tests will used to assess diﬀerences
between simulated and real ablation lesion volumes. The contributions
of factors such as cirrhosis, ablation duration, tissue perfusion, and
tumor size to volume and surface deviations will be investigated in
separate multivariate linear regression models. Eﬀect sizes of multi-
variate linear regression models will be given as mean ± standard
deviation and [95% conﬁdence limits].
To deﬁne the accuracy of the simulation as a parameter, we in-
troduce the following categories:
Based on the ratio of segmented to simulated lesion volume the
results are categorized as follows:
a)
I seg/sim<60% (much smaller)
II 60% ≤ seg/sim<80% (smaller)
III ≤80% seg/sim ≤120% (comparable)
IV 120% < seg/sim ≤140% (larger)
V seg/sim>140% (much larger)
b) If the simulated lesion is comparable with the real lesion based on
a), we further investigate the accuracy based on the following two
metrics namely, sensitivity (SN) and average absolute error. We
introduce the rating level between 1 and 5 for the simulated lesion
based on two metrics as explained below. Simulation rating based
on average absolute error:
1 If average absolute error> 5
2 If 4 < average absolute error ≤5
3 If 3.5 < average absolute error ≤4
4 If 3 < average absolute error ≤3.5
5 If average absolute error ≤3
Here, the average absolute error is computed by trilinear inter-
polation from the distance level set at the center of the face and
weighted over the area of the triangle face, per-vertex metrics have
equal weight. Sensitivity is deﬁned as the ratio between common vo-
lume of the segmented and simulated lesions to the segmented lesion
volume.
Simulation rating (based on volume deviation):
1 If SN ≤ 50
2 If 50 < SN ≤ 60
3 If 60 < SN ≤ 70
4 If 70 < SN ≤ 80
5 If SN > 80
c) We take the average of the rating level obtained from the average
absolute error and sensitivity. If the average rating level is:
I < 3, then real and simulated lesion strongly diﬀer.
II ≥ 3, then real and simulation do not diﬀer strongly.
Further details on lesion comparison are described elsewhere [9].
Secondary endpoints are.
a) Eﬃciency of workﬂow steps
I Proof of the procedures feasibility
• Is the procedure stable enough for clinical routine (yes/no)?
II Duration of the simulation
• Would it have been short enough to be feasible in clinical
practice (yes/no)?
Table 6
Ablation protocol for 5-cm ablation (RITA Medical, Boston Scientiﬁc).
Deploy to Target temp Power Timer Heating duration
2 cm 105 °C 150 W 15 min Until target temp. is reached, then deploy to 3 cm
3 cm 105 °C 150 W 14.5 min Until target temp. is reached, then deploy to 4 cm
4 cm 105 °C 150 W 14 min 7 min after target temp (i.e., after hearing the beep, wait 7 min), then deploy to 5 cm
5 cm 105 °C 150 W 7 min 7 min after target temp (i.e., after hearing the beep wait 7 min), then deploy cool down
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b) Would the treatment protocol have been inﬂuenced by the simula-
tion results if they would have been known prior to the treatment.
I Inﬂuence Yes/No
• If yes, is there an expectable potential beneﬁt for the patient
due to a modiﬁcation of the treatment protocol?
II Does the follow up (3, 6, 12 months) imaging support these as-
sumptions regarding local tumor control
• The tumor is completely treated with suﬃcient safety margins;
healthy tissue has been largely spared by the ablation and there
is no loco regional recurrence visible in the follow up imaging
(= loco regional recurrence free survival).
• The tumor (including safety margins) is completely treated, but
lots of healthy tissue has been damaged with the risk of serious
complications.
• The tumor is treated incompletely or there is a visible recurrent
tumor in the follow up examination.
3. Discussion
We introduced the ﬁrst prospective multicenter clinical trial for the
evaluation of a software application, developed to predict RFA induced
hepatic tissue necrosis in patients with early liver cancer [9,10]. After
developing a prototype in the European Union - funded IMPPACT
project we carried out comprehensive improvement of the usability
(e.g. performance, system stability, and ergonomics), integration of
patient speciﬁc perfusion data, and adaption to the clinical workﬂow.
The aim of the proposed prospective multicenter phase 2b exploration
clinical trial (ClinicIMPPACT, according IDEAL criteria – 36) is to de-
termine the accuracy of the lesion prediction and the eﬀectiveness of
the software tool to assist interventional radiologist in clinical routine -
radiofrequency ablation of liver tumors.
RFA nowadays serves as a common ﬁrst- and second line treatment
for several malignancies in diﬀerent organ systems, including liver,
kidney, lung, and bone. Successful treatment of neoplastic lesions is
deﬁned by complete tumor destruction, which can be evaluated by
follow up imaging (mainly Ultrasound, MRI, and CT, usually performed
1 month after treatment). Monitoring the size of tissue necrosis during
the RFA-procedure however is a challenging task and there is currently
no reliable method commercially available. Thus, there is a signiﬁcant
rate of under- and overtreatment after RFA using the standard protocols
recommended by the manufactures. Overtreatment potentially com-
promises sensitive surrounding structures and increases the complica-
tion rate. Under treatment leads to incomplete tumor destruction and
subsequently to tumor recurrence. Hence, regularly the interventionist
modiﬁes the standard treatment protocol according to his/her experi-
ence. It can be assumed, that this might be the reason, why patient
outcomes are strongly dependent on the experience of the interven-
tionist [33]. Despite new developments in depiction and prediction of
the ablation zone remains diﬃcult. To overcome this speciﬁc problem,
accurate simulation of the RFA lesion before ablation will potentially
improve treatment outcome and will elevate the learning curve for less
experienced interventionists.
To better understand the complex mechanism of heat induced tissue
necrosis, extensive cell and animal experiments were performed in the
previous project: IMPPACT, The 7th Framework Program for Research
of the European Union. These results were used to establish a cell death
equation and to engineer a dedicated algorithm to compute the tissue
necrosis in a patient speciﬁc computer model [34]. During IMPPACT,
mismatches between simulated and real lesions were seen for some
lesion shapes, which could be explained by errors in the segmentation
of radiological images. Data processing took about 5 h, and was
therefore not feasible for intraprocedural clinical use. Therefore, a
clinical adaptation of the model required several improvements related
to predictive power, ergonomics, computational performance and the
seamless integration into the clinical workﬂow. Several individual
factors are aﬀected by inner body structures (blood ﬂow, liver tissue
properties, tumor type and perfusion, proximity to vessels and liver
surface, etc.) that substantially aﬀect the size and conﬁguration of the
ablated lesion. None of these factors are taken into account in the
available manufacturers' ablation protocols. We believe that based on
the results of the ClinicIMPPACT project the available simulation tool
could be optimized for clinical use and might potentially predict the
size and shape of a RFA treatment precisely. Using a dedicated RFA
protocol and including patient speciﬁc data (e.g. liver perfusion quan-
tiﬁcation data) will further improve the simulation outcomes.
Compared to the ﬁrst prototype, the software has been signiﬁcantly
improved in regards to processing speed, ergonomical use, and it now
adequately respects the clinical workﬂow. Therefore, the highly com-
plex simulation algorithm of the previous project was optimized and
accelerated with a newly developed numerical solver to fulﬁll clinical
time restrictions.
Preliminary validations with patient data from clinical routine in
the four medical institutions participating in the projects show that the
graphical user interface is “physician friendly” and runs stable (9,10).
The calculation times to prepare the patients 3D model are feasible for
the users. There are several reports about software tools assisting
thermal ablation of liver tumors. Some of them support treatment
planning and placing of the probe [35,36]. Others allows simulation of
the thermal necrosis and cooling eﬀects due to vessels with numerical
models and fast approximations [37].
Schumann et al. report an evaluation of the suitability of these
methods in a retrospective clinical study [30]. For a precise simulation
of the ablation zone after RFA multiple criteria have to be considered.
Unfortunately, in clinical routine several of these parameters, e.g. the
precise localization of the probe and the full ablation protocol or in-
dividual perfusion values of the liver are not documented. Due to this
fact, a retrospective evaluation is always prone to error. To the best of
the author's knowledge there is no validation of accuracy and eﬃciency
of software for prediction of RFA-induced necrosis in the liver in a
prospective clinical trial. The primary endpoint of the proposed phase
2a clinical trial will be quantiﬁcation of the accuracy of the method.
Secondary endpoints will investigate the functionality of the applica-
tion in various clinical workﬂow environments. One potential draw-
back of the study is the lack of a randomized control group, which
represents an imposed restriction from the institutional review board.
We will address this issue by the analysis of a matched, retrospective
control group, e.g. comparing intervention durations.
Once reliable accuracy of the prediction and functionality of the
overall system is assured CE-marking will be requested. The clinically
validated and certiﬁed tool will potentially help to gain wider accep-
tance by the radiology community and might be implemented into fu-
ture routine RFA of liver tumors. Further randomized clinical trials are
needed to test whether the use of this tool improves patient outcome.
Finally, an adaption of this tool could be evaluated for the minimal
invasive treatments of cancers in other organs with diﬀerent techniques
(e.g. cryoablation and microwave ablation).
In summary, this ﬁrst of its kind multicenter clinical trial aims at the
clinical integration of a dedicated software solution to accurately pre-
dict lesion size and shape after radiofrequency ablation of liver tumors.
As mispredictions of true ablation zones can lead to increased tumor
recurrence due to under treatment or complications due to over-
treatment this tool will be of great interest to the interventional radi-
ologist community.
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